logo
I'm An ER Physician. Here Are 5 Types Of Pain I'd Never Ignore.

I'm An ER Physician. Here Are 5 Types Of Pain I'd Never Ignore.

Yahoo19 hours ago

When it comes to severe medical situations, emergency medicine doctors see it all. They're the physicians who folks of all ages rush to when something serious goes wrong. But just what does 'serious' mean? What kinds of pain constitute a visit to the emergency department? Experts say that it's a hard question to answer.
'Unfortunately, it can be so variable from patient to patient, and sometimes people that even have minor pain may have something very serious going on. So [pain is] not something that anybody should ignore,' said Dr. Michael Turturro, a professor of emergency medicine at the University of Pittsburgh School of Medicine.
Meaning, you should take pain seriously and see a doctor if you have any concerns. It's better to be told nothing is wrong than to regret not seeing a medical professional sooner. (We know there are financial considerations that come along with this — more on that below.)
While all pain is worth taking seriously, experts told HuffPost there are certain pains that are generally across-the-board alarming and reason enough for medical attention. Here's what they are:
'Generally, pain that is sudden and severe and does not go away is something that should really get your attention,' Turturro said. This goes for pain anywhere on your body, he noted.
A medical professional will need to evaluate the pain and determine if it's serious or not, but if you have a sudden and alarming new pain, it's a good idea to get it checked out and not to ignore it.
'We'd rather people err on the side of caution,' Turturro added. 'If they're concerned enough that they feel something is not right and they need to be evaluated, then they should be evaluated whether or not it's related to something serious or not.'
Say you're worried about new hand pain that came out of nowhere. Instead of brushing it off, consider seeing a doctor.
'If it's concerning enough that it is troubling to you, and particularly if it's a pain you've never experienced before, that's something you should really consider getting urgent medical attention for,' he added.
Chest pain is often (and rightfully) associated with heart attacks, which makes this type of pain important to take seriously.
'Chest pain is definitely a concerning one to us. If people are developing that sudden onset of chest pain, something they've never felt before, or they've had it before [and] they've been told that they have heart problems, they should be checked out sooner rather than later,' said Dr. Mark Conroy, emergency medicine physician at the Ohio State University Wexner Medical Center.
Turturro said chest pain is particularly worrisome in older people and for folks who have risk factors for heart disease, such as hypertension, diabetes and high cholesterol.
Beyond heart attacks, sharp chest pain could also mean other serious issues, such as a blood clot in the lung or a tear of major vessels in the chest, Turturro said.
But it's impossible to say exactly what chest pain could signify in one person versus another, and it isn't always serious. 'Chest pain could be rather related to very benign causes as well, such as heartburn,' Turturro added.
Since lots of things can manifest as chest pain, you shouldn't totally panic, but you also shouldn't discount your chest pain (or, once again, any pain). Instead, you should see a doctor who can determine what's going on.
According to Conroy, lower leg pain, specifically in the calf, can be worrisome when it's accompanied by leg swelling and/or redness of the calf.
'I always get concerned that they might have the concerning symptoms for a blood clot, or what we call a DVT, deep venous thrombosis,' Conroy said.
'That would be a concerning pain that I would definitely want someone to get seen sooner rather than later for, especially if they recently had surgery and they've been just laying in bed, or ... they had a long plane ride recently,' he noted.
Back pain is a common affliction that can happen in a number of scenarios, such as sleeping in a bad position, working out improperly, sitting in a chair that doesn't provide support and more. While it's always worth taking care of your back pain, there is one specific type that Conroy said needs medical attention.
If you have back pain that feels like a tearing sensation through your upper back or at the back of the chest,you should see a professional as soon as possible.
'Having that tearing sensation can represent a problem with the main large blood vessel in your body, called the aorta,' Conroy said.
'The abdomen is one of those [pains] I think every emergency physician gets a little bit nervous about because there's just so many things that can go on,' Conroy said. 'So instead of specific conditions, it's really more, how are the symptoms presenting?'
'If you're having abdominal pain, or what we call flank pain ... kind of the right or left portion of your lower back or lower abdomen, then certainly that could be concerning for things like kidney stones, or if you're having fevers with it, it can be a kidney infection,' he said.
It could also be appendicitis if the flank pain is accompanied by nausea and vomiting, Conroy added.
If you have this kind of lower abdominal pain along with any of the above problematic symptoms, it's a good idea to see a doctor quickly.
While going to the doctor, and especially an emergency medicine department, can feel foreboding, you should never ignore or dismiss your pain.
Seeing a doctor about an alarming problem is the best move for your health, even if the pain ends up being nothing at all — which is the ideal outcome.
'It may be that you get a brief evaluation, you get some kind of screening labs or screening tests, and hopefully, some reassurance that the worst-case scenario is not what's going on,' Conroy said.
It can certainly be frustrating to hear nothing is wrong while still having to pay for health care costs, particularly if you're paying emergency room prices, which tend to be much higher than routine visits or scheduled specialist visits.
If you need fast medical attention but not emergent medical attention, you can consider visiting your local urgent care, which tends to be cheaper than a visit to the ER. You can also call your primary care provider's office to see if they have after-hours or last-minute appointments available, which would also be cheaper than an ER visit. That said, certain issues do require immediate emergency department visits and are worth the cost for your safety. Urgent care staff or your doctor should be able to help you determine if emergency care is needed — and, if you're not sure if you need emergent attention, it's best to go to the ER.
I'm A Colorectal Cancer Doctor. Here Are 5 Things I'd Never Do.
If Your Stomach Pain Feels Like This, It's Time To Go To The ER
7 Things ER Doctors Say You Should Always Do After A Fall

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Yahoo

timean hour ago

  • Yahoo

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

timean hour ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition

Yahoo

timean hour ago

  • Yahoo

Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store